Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Voorraadrapport

Marktkapitalisatie: US$20.7m

Cyclo Therapeutics Beheer

Beheer criteriumcontroles 4/4

Cyclo Therapeutics' CEO is N. Fine, appointed in Sep 2015, has a tenure of 9.17 years. total yearly compensation is $672.89K, comprised of 80.4% salary and 19.6% bonuses, including company stock and options. directly owns 2.59% of the company’s shares, worth $536.73K. The average tenure of the management team and the board of directors is 7.3 years and 10 years respectively.

Belangrijke informatie

N. Fine

Algemeen directeur

US$672.9k

Totale compensatie

Percentage CEO-salaris80.4%
Dienstverband CEO9.2yrs
Eigendom CEO2.6%
Management gemiddelde ambtstermijn7.3yrs
Gemiddelde ambtstermijn bestuur10yrs

Recente managementupdates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Analyse CEO-vergoeding

Hoe is N. Fine's beloning veranderd ten opzichte van Cyclo Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$673kUS$541k

-US$20m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$541k

-US$15m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$508k

-US$14m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$489kUS$400k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$490kUS$400k

-US$8m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$467kUS$400k

-US$4m

Sep 30 2018n/an/a

-US$4m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$441kUS$400k

-US$4m

Compensatie versus markt: N.'s total compensation ($USD672.89K) is about average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: N.'s compensation has been consistent with company performance over the past year.

CEO

N. Fine (67 yo)

9.2yrs

Tenure

US$672,888

Compensatie

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
N. Fine
CEO & Director9.2yrsUS$672.89k2.59%
$ 536.7k
C. Strattan
Founder & Directorno dataUS$33.00k1.06%
$ 220.4k
Joshua Fine
CFO & Secretary10.8yrsUS$463.98k0.059%
$ 12.2k
Michael Lisjak
Senior VP of Business Development & Chief Regulatory Officer5.3yrsUS$473.21k0.043%
$ 8.9k
Jeffrey Tate
COO, Chief Quality Officer & Director9.2yrsUS$255.14k0.32%
$ 66.4k
Lori McKenna
Global Head of Patient Advocacy3.5yrsgeen gegevensgeen gegevens
Karen Mullen
Interim Chief Medical Officer1.8yrsgeen gegevensgeen gegevens

7.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: CYTH's management team is seasoned and experienced (7.3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
N. Fine
CEO & Director10.8yrsUS$672.89k2.59%
$ 536.7k
C. Strattan
Founder & Director34.8yrsUS$33.00k1.06%
$ 220.4k
Jeffrey Tate
COO, Chief Quality Officer & Director14.3yrsUS$255.14k0.32%
$ 66.4k
William Shanahan
Independent Director8.4yrsUS$40.13k0.47%
$ 96.5k
Markus Sieger
Independent Chairman10.8yrsUS$66.38k1.21%
$ 250.5k
Rita Colwell
Co-Chair of Scientific Advisory Boardno datageen gegevensgeen gegevens
Sharon Hrynkow
Co-Chairman of Scientific Advisory Board10yrsUS$600.09kgeen gegevens
F. Ostronic
Independent Vice Chairman10.6yrsUS$41.25k1.22%
$ 251.7k
Caroline Hastings
Member of Scientific Advisory Board9.7yrsgeen gegevensgeen gegevens
Benny Liu
Member of Scientific Advisory Board9.5yrsgeen gegevensgeen gegevens
Gerald F. Cox
Member of Scientific Advisory Board3.2yrsgeen gegevensgeen gegevens
Randall Toig
Independent Director6.7yrsUS$35.63k0.44%
$ 90.7k

10.0yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: CYTH's board of directors are seasoned and experienced ( 10 years average tenure).